Targeting ID to Inhibit the Vascularization of Breast Tumors
Final rept. 25 Sep 2000-24 Sep 2001
SLOAN-KETTERING INST FOR CANCER RESEARCH NEW YORK
Pagination or Media Count:
Under the auspices of this Army Concept Award we have begun the derivatization of a compound AIL, for anti-Id lead shown to bind to the Id proteins, known to be required for the formation of blood vessels into breast tumors. We have identified sites on AIL that can be modified and have begun the chemistry of adding a linker to this region of the molecule that can accept geldanamycin. The AIL-geldanamycin fusion will be used to target the Id proteins for degradation in human cancers and thereby inhibit tumor angiogenesis.
- Anatomy and Physiology
- Medicine and Medical Research